Protecting a Way of Life in Haiti | Boehringer Ingelheim US
Click here to find out how Boehringer Ingelheim is helping to protect a way of life in Haiti by producing a custom swine vaccine to support the island.
Search
Sites Around the World
Click here to view our biggest sites. With 52,000 employees worldwide, Boehringer Ingelheim has a research and production network across the globe.
From Finance to Pharma
From Finance to Pharma
Boehringer Ingelheim launches vaccine to protect poultry from three diseases
Boehringer Ingelheim launches vaccine to protect poultry from three diseases
Boehringer Ingelheim hosts Governor Lamont press conference at our Apple Blossom learning center to support more on-site childcare options in Connecticut
Read about Connecticut Governor Ned Lamont and his administration’s visit to our U.S. headquarters in Ridgefield to tour our Apple Blossom Children’s Learning Center, to express the need for more childcare options for local communities and businesses.
Daniel Kiesenhofer
Daniel Kiesenhofer talks about his role as Project Manager Quality Control at Boehringer Ingelheim in Vienna, Austria.
Dr. Anna Dieckmann and Dr. Lorenz Maier
Here is the story of Dr. Anna Dieckmann and Dr. Lorenz Maier's successful partnership. For more talent insights, visit our Careers Page.
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta
Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta
Scleroderma
Scleroderma
Nadine Becker
Nadine Becker, speaks about her role in the Master Data Management and her 20 year career in Boehringer Ingelheim.
African Swine Fever: Important Facts | Boehringer Ingelheim US
Click here to read more on the Boehringer Ingelheim efforts to understand and create a vaccine to prevent African Swine Fever in livestock across the globe.
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
Heart Diseases
Heart Diseases
Tomorrow leaders
We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.
An Employee’s Commitment to Ensuring Access to Medicines
An Employee’s Commitment to Ensuring Access to Medicines
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
Pets
Pets
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Prioritizing mental health and well-being today and every day
Prioritizing Mental Health and Well-being Today and Everyday
Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US
Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.
Boehringer Ingelheim announces InPedILD PhaseIII trial results
Boehringer Ingelheim announces InPedILD PhaseIII trial results
Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative
Read more on how the Boehringer Ingelheim heartworm disease prevention initiative has helped more than 51,000 dogs receive care across the USA in 2020.